Navigation Links
Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
Date:9/6/2008

dose levels (p= 0.0126). The adaptive study design used could identify doses giving a headache response in 50-75% of patients. It did not explore the maximum possible efficacy of the drug.

COL-144 was generally well-tolerated with no serious adverse events or withdrawals due to non-serious adverse events. The most common adverse event was paresthesia, which was usually mild and transient, resolving rapidly after cessation of the infusion. No patient reported triptan-like chest symptoms in relation to the COL-144 infusion. No clinically significant changes were seen in vital signs or ECG parameters.

"We identified doses of 20 mg and higher as doses of interest for further evaluation in future studies, and we plan to continue the clinical development of COL-144, using an oral formulation," added Dr. Pilgrim.

About CoLucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's pipeline includes COL-144, a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at http://www.colucid.com.


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...stCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq:...ovember 10, 2009 at 8:30 a.m. EST to discuss the t...utlook for the remainder of 2009. Ron Bentsur, Ch...e call. Keryx will announce its financial results...rior to the call. ,, In order to participate in...
(Date:11/6/2009)...- NexBio Inc., in collaboration with scientists at...DC), St. Louis University, and the University of H...rticles in the peer-reviewed journal PLoS ONE. Th...dase ® ) may play a potentially important rol... Influenza A(H1N1) and drug-resistant influenza. ...
(Date:11/5/2009)...ire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE )...cts for regenerative healing, today reported finan... 30, 2009. ,, "During the third quarter of 2009...ologic products MagniFuse(TM) Bone Graft, FacetLi...tive Grafting," said Sam Owusu-Akyaw, President an...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Journal of Midwifery 26amp 3B Womens Health honors outstanding authors 54619 1Journal of Midwifery 26amp 3B Womens Health honors outstanding authors 54619 2Nucleix Appoints Meirav Chovav Vice President of Strategic Affairs and to the Board of Directors 13591 1Nucleix Appoints Meirav Chovav Vice President of Strategic Affairs and to the Board of Directors 13591 2Nucleix Appoints Meirav Chovav Vice President of Strategic Affairs and to the Board of Directors 13591 3Imagenetix Inc Announces Interview With Bloomberg Radio 13589 1Imagenetix Inc Announces Interview With Bloomberg Radio 13589 2
...07 - ApoCell, Inc. presented the,results of a stud...icago and ApoCell at the 2007 annual meeting of th...d in Chicago in early June.,The study showed that ... technology provides reliable predictive data of c... treating aggressive head,and neck cancer patients...
...e 08, 2007,/PRNewswire-FirstCall/ --Eurand to pres...ciety Annual,Meeting. ...e pancreatic insufficiency (EPI) is a,deficiency o...,the pancreas that can result from a number , , ...c pancreatitis, and , , pancreatic cancer , ...
Other Medicine Technology:ApoCell's Cancer Predictive Index Helps Oncologists Select the Most,Effective Targeted Drug Therapy 2Eurand to Present Zentase Phase III Data 2Eurand to Present Zentase Phase III Data 3
(Date:11/6/2009)...ST. LOUIS, Nov. 6 Centene Corporation (NYSE: CNC...oming healthcare conferences over the next few wee... Health Care Conference, to be held November 11-13...Phoenix, Centene will present Wednesday, November ...er interested parties may access Centene,s present...
(Date:11/6/2009)...WASHINGTON, Nov. 6 Plan International, a leadin... in 66 countries around the world, has been asked ...h and well-being at the upcoming American Public H...position in Philadelphia, Pennsylvania on November...ation gathers organizations together to address cu...
(Date:11/6/2009)...eck out pharmacy, clinic and government programs, ...News) -- The recession has made it more difficult ...cription medications, but several options are avai...ty in Indianapolis. , First, talk to your pharmaci...and assistant professor of pharmacy practice at Bu...
(Date:11/6/2009)... WAVonline - the Value-Add..., and WaveRider® Product Lines , ... the value-added distributor of wireless, security...t, announced that it has partnered with Vecima Net...ent supporting broadband access to cable, wireless...
(Date:11/6/2009)...Statement by James P. Firman, President and CEO of.... 6 The National Council on Aging urges the House...t (H.R. 3962), which we regard as a historic step ...ealth care for Americans of all ages. ,, After a c... is a good deal for America,s seniors. H.R. 3962 w...
Breaking Medicine News(10 mins):Health News:Centene Corporation to Present at Upcoming Healthcare Conferences 2Health News:Plan's Expertise Highlighted at Premier Health Forum 2Health News: Pay Less for Prescription Drugs 2Health News:WAV Distribution Partners with Vecima Networks Inc. 2Health News:WAV Distribution Partners with Vecima Networks Inc. 3Health News:NCOA Supports H.R. 3962, the Affordable Health Care for America Act 2
... people who eat breakfast regularly have a lower r...searchers found from the Children’s Hospital in Bo...ce syndrome was 35-50 per cent lower among people ..., high abnormal body fat and high blood pressure. ...
...ch easier than earlier and according to James Well...rgeons (ASPS), many people, both men and women are...ntrary to the past, when patients would wait until...ve increased 25%)// and collagen injections (which...
...er Cancer Institute, led by Glenn Dranoff, MD,have...Clinical Oncology that vaccines made from patients...d make them a powerful new treatment for deadly ca...udy researchers have developed a vaccine that gets...
...on which causes clotting in the veins. Typical the...o 10-day course of heparin followed by three to 12...oblem with this treatment is that once the patient...revious studies, it// also puts the patient at an ...
...ion of The Anatomical Record has put together a co... injury repair in animals. Spinal cord injury affe...em with little hope of living a normal life. Howev...lved in such disabling injuries. Researchers from/...
...o the DNA within our cells, which could lead to ca...le that triggers a protective mechanism in the bod...ely damaged cells to destroy themselves. The molec...ridge. MDC1 is believed to play a key role in prot...
Other Medicine News:Health News:New lung cancer vaccine on the anvil 2Health News:Treatment over a longer period for blood clotting 2
...rogram offers state-of-the-art quality in an instr...strength and durability. Low profile cutting tips ...eries I instruments are available in just about ev... large and small joint arthroscopic procedures.,A...
...rogram offers state-of-the-art quality in an instr...strength and durability. Low profile cutting tips ...eries I instruments are available in just about ev... large and small joint arthroscopic procedures.,A...
...s facilitates fast and effective resection of meni... shaped meniscal rim. The flat, crescent-shaped ti...tightest joint spaces. Made in the U.S. at Arthrex...nce in arthroscopy hand instrument design guarante...
...s facilitates fast and effective resection of meni... shaped meniscal rim. The flat, crescent-shaped ti...tightest joint spaces. Made in the U.S. at Arthrex...nce in arthroscopy hand instrument design guarante...
Medicine Products: